Sermorelin


Concise Prescribing Info
Indications/Uses
Diagnosis of growth hormone deficiency.
Dosage/Direction for Use
Adult : IV 1 mcg/kg in the morning after an overnight fast. Must use w/ other tests to establish a diagnosis.
Dosage Details
Intravenous
Diagnosis of growth hormone deficiency
Adult: 1 mcg/kg in the morning after an overnight fast. Must be used in conjunction with other tests to establish a diagnosis.

Subcutaneous
Growth hormone deficiency
Child: 30 mcg/kg once daily at bedtime.
Special Precautions
Not to be used in children whose growth hormone response to stimulation tests is inadequate. DM or epilepsy. Evaluate thyroid status before and during therapy. Uncontrolled hypothyroidism, obesity, elevated plasma fatty acids. Treatment should be stopped once epiphyses have closed. Pregnancy, lactation.
Adverse Reactions
Tightness in the chest, facial flushing, urticaria, pain at the inj site, headache, nausea, vomiting, dysgeusia.
Drug Interactions
Preparations that contain or release somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors may interfere with the diagnostic efficacy. Serum levels of growth hormone may be increased when used with clonidine and levodopa. Efficacy may be reduced when used with antimuscarinic or antithyroid drugs.
Lab Interference
May increase serum levels of inorganic phosphorus and alkaline phosphatase.
Action
Description: Sermorelin is a synthetic 29-amino acid peptide that corresponds to the amino-terminal segment of the growth hormone releasing hormone. It stimulates the pituitary gland to increase the release of growth hormone.
Pharmacokinetics:
Absorption: Average bioavailability after SC admin is about 6%.
Excretion: Rapidly cleared from circulation. Half-life is about 11-12 min after IV or SC admin.
Storage
Store at 2-8°C.
Disclaimer: This information is independently developed by MIMS based on Sermorelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in